Kidney Cancer Survival Rate |
Experts have continued to accumulate relevant study in regards to the various kinds of cancer in the kidney and have been able to come up with reasonably consistent statistics. Throughout this research, one type of kidney cancer has proven to be much more prevalent than others. This kind of kidney cancer is called renal cell carcinoma-and it is the kidney cancer for which survival rates are usually based upon.
A kidney cancer survival rate is usually shown as the ratio of cancer patients who have had the similar type of cancer and the same stage of cancer, and who have managed to stay alive for a specific length of time. This period of time is normally 5 years-which means that kidney cancer patients made it for at least 5 years after their diagnosis. Obviously, a kidney cancer survival rate is a general figure based on a number of cases. No person, not even the doctor, can calculate particularly the period of time an individual can survive right after the diagnosis of the disease.
Here are the 5 year kidney cancer survival rates based on the stage of the kidney cancer:
- Stage 1: 81%
- Stage2: 74%
- Stage 3: 53%
- Stage 4: 8%
As outlined by this statistics, the average rate of survival for patients of renal cell carcinoma during this 5 year period was around 54%.
Here are the 5 year kidney cancer survival rates based upon gender and race
- Caucasian women: 65%
- Caucasian men: 65%
- African-American men: 62%
- African-American women: 66%
Kidney Cancer Survival Rate |
To give you an idea, the statistics concerning the stage of kidney cancer diagnosis is listed below:
- 53% of cases are diagnosed before the spread of the cancer (localized)
- 20% of cases are diagnosed after the spread of the cancerous cells to organs and tissues close to the kidneys (regional)
- 22% of cases are diagnosed after the spread of the cancer to organs and tissues far beyond the kidneys (distant)
Naturally, cases which were identified during the early stages corresponded to a higher kidney cancer survival rate.